Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
Latest news on INCYTE CORPORATION
02/21 INCYTE : to Present at Upcoming Investor Conferences
02/21 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Entry into a Material Definitive..
02/21 INCYTE CORP : Entry into a Material Definitive Agreement, Unregistered Sale of E..
02/16 ELI LILLY AND : EC approves Eli Lilly's rheumatoid arthritis drug
02/15 INCYTE : Additional results from pivotal RA-BEAM study published in New England ..
02/15 AGENUS INC. (NASDAQ : AGEN) Files An 8-K Entry into a Material Definitive Agreem..
02/15 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Results of Operations and Financ..
02/15 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Entry into a Material Definitive..
02/14 INCYTE CORP : Entry into a Material Definitive Agreement, Regulation FD Disclosu..
02/14 INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
02/14 NETWORKNEWSBREAKS – AMENDED CO : AGEN), Incyte Corp. (NASDAQ: INCY) Shares..
02/14 INCYTE : INCY) Gains on Agenus Deal
02/14 NASDAQ 100 MOVERS : Logm, incy
02/14 INCYTE CORP : Results of Operations and Financial Condition, Financial Statement..
02/14 INCYTE : tops Street 4Q forecasts
02/14 INCYTE : Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 20..
02/13 ELI LILLY AND : European Commission Approves Once-Daily Olumiant Tablets for Tre..
02/13 INCYTE : NICE approves Incyte’s leukaemia drug for routine NHS use
02/09 INCYTE : and Calithera Biosciences Announce Global Collaboration to Develop and ..
02/09INCYTE CORPORATION : annual earnings release
02/06 IMMUNOVACCINE : IMV; IMMVF) Lead Immuno-Oncology Candidate to Enter Investigator..
01/31 CALITHERA BIOSCIENCES INC (NASDAQ : CALA): What You Need To Know
01/31 INCYTE : and Calithera Biosciences Announce Global Collaboration to Develop and ..
01/31 CALITHERA BIOSCIENCES, INC. (NASDAQ : CALA) Files An 8-K Entry into a Material D..
01/30 INCYTE : strikes drug development deal with California company
01/25 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Other Events
01/24 INCYTE : to Report Fourth Quarter and Year-End Financial Results
01/23 INCYTE CORP : Other Events (form 8-K)
01/19 INCYTE : and Merck to Advance Clinical Development Program Investigating the Com..
01/19 INCYTE : Studies from Incyte Add New Findings in the Area of Pharmacokinetics (P..
01/17 NASDAQ 100 MOVERS : Incy, dltr
01/16 ELI LILLY AND : FDA extends review period for Eli Lilly's rheumatoid arthritis d..
01/13 INCYTE : U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheu..
01/12 NASDAQ 100 MOVERS : Swks, incy
01/10 INCYTE : and Merck to Advance Clinical Development Program Investigating the Com..
01/09 NASDAQ 100 MOVERS : Vod, incy
01/06 INCYTE : New Toxicology and Pharmacology Findings from Incyte Discussed [Results..
01/04 KURA ONCOLOGY : Appoints Steven Stein, M.D. to Board of Directors
2016 INCYTE : Announces First Patient Treated in Pivotal Clinical Trial Program for R..
2016 INCYTE : and Merus Announce Global Strategic Research Collaboration to Discover ..
2016 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Entry into a Material Definitive..
2016 INCYTE CORP : Entry into a Material Definitive Agreement, Regulation FD Disclosu..
2016 INCYTE CORP : Entry into a Material Definitive Agreement (form 8-K)
2016 INCYTE : CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Ad..
2016 INCYTE : to Present at Upcoming Investor Conference
2016 AGENUS : Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpo..
2016 NASDAQ 100 MOVERS : Incy, cost
2016 NASDAQ 100 MOVERS : Incy, wdc
2016 INCYTE : Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supp..
2016 INCYTE : CURE Magazine Hosts 4th Annual Gala Honoring MPN Heroes
2016 INCYTE : CURE® Magazine Hosts 4th Annual Gala Honoring MPN Heroes®
2016 AGENUS INC. (NASDAQ : AGEN) Files An 8-K Other Events
2016 INCYTE : New Analyses of Phase 3 Trials Show Improvements in Rheumatoid Arthriti..
2016 INCYTE : Baricitinib Demonstrates Early Response Compared to Placebo and Signifi..
2016 INCYTE : to Present at Upcoming Investor Conference
2016 INCYTE : and GENESIS Pharma Announce a Commercialization Agreement for Iclusig® ..
2016 INCYTE : More Than 20 Abstracts Highlighting Data from Incyte’s Portfolio ..
2016 INCYTE : to Present at Upcoming Investor Conference
2016 INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
2016 INCYTE CORP : Results of Operations and Financial Condition, Financial Statement..
2016 INCYTE : Reports 2016 Third-Quarter Financial Results and Updates Key Clinical P..
2016 INCYTE : posts solid earnings performance in third quarter
2016 AGENUS INC. (NASDAQ : AGEN) Files An 8-K Reports Third Quarter Financial Results..
2016INCYTE CORPORATION : quaterly earnings release
2016 NASDAQ 100 MOVERS : Incy, mat
2016 INCYTE : to Report Third Quarter Financial Results
2016 NASDAQ 100 MOVERS : Lbtyk, incy
2016 INCYTE : CURE Magazine to Host Recognition Gala for Heroes in Rare Blood Cancer ..
2016 INCYTE : Additional Phase 1 Data from ECHO-202 Reinforce Durability of Response ..
2016 NASDAQ 100 MOVERS : Tsla, lrcx
2016 NASDAQ 100 MOVERS : Payx, incy
2016 INCYTE : Updated Phase 1 Data Reinforce the Clinical Profile of Epacadostat in C..
2016 INCYTE : NCCN Guidelines® Recommend Jakafi® (ruxolitinib) for the Treatment of M..
2016 NASDAQ 100 MOVERS : Ntes, wdc
2016 NASDAQ 100 MOVERS : Incy, swks
1  2  3  4  5  6Next
Advertisement
Financials ($)
Sales 2017 1 586 M
EBIT 2017 150 M
Net income 2017 125 M
Finance 2017 178 M
Yield 2017 -
P/E ratio 2017 278,54
P/E ratio 2018 121,32
EV / Sales 2017 14,4x
EV / Sales 2018 13,6x
Capitalization 22 987 M
More Financials
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | 4-Traders
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 138 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
David W. Gryska Chief Financial Officer & Executive Vice President
Reid M. Huber Chief Scientific Officer & Executive VP
Steven H. Stein Chief Medical Officer & Senior Vice President
Paul Alan Brooke Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION22.03%22 987
QUINTILES IMS HOLDINGS..0.26%18 233
CELLTRION, INC.--.--%10 892
LONZA GROUP AG2.67%10 437
SEATTLE GENETICS, INC.24.46%9 141
ALKERMES PLC-2.50%8 129
More Results